So now, now that brnciattib is approved uh for, for patients with bronchiectasis, the question, of course, is which patients will benefit the most uh from being on this medication. And I, you know, it, it obviously fits into our concept of the vicious cycle or the vicious vortex where the treatment of inflammation, um, you know, may ultimately be disease modifying. So, you know, the question is, do we need to follow the enrollment uh criteria that were used in the clinical aspen trial where patients had two or more exacerbations, or is there a broader patient population who really would benefit from using rancicaib? We know this bronchiectasis disease is very heterogeneous and also somewhat unpredictable, although there are some prognostication markers that we can identify early in our course of, of evaluating the patient. Things like recurrent exacerbations, of course, that, that treatable trait or phenotype of the frequent exacerbator. Patients who are chronically infected with pseudomonas. Um, you know, older patients, patients who are underweight. So, I, I do think, um, that you have to do your due diligence when you evaluate the patient and, you know, we've stressed a lot the importance of a personalized evaluation and treatment plan for the patient. I don't really envision prescribing renzacattib as my, uh, you know, initial visit, uh, go home with the medication prescription. I really think we have to take time to look for uh identifiable, uh, cause that can be mitigated. We need to train the patient, educate the patient about the disease itself. Uh, in, in, um, indoctrinate the patient, if you will, into the concepts of airway clearance. We wanna identify what, uh, infection the patient may be chronically and, um, you know, chronically carrying, whether they're pseudomonas or whether they have non-tuberculous mycobacterium. But clearly, after you've done this evaluation, you're gonna be able to phenotype uh your patient, your individual patient much better and then come to a decision about where uh the DPP1 inhibitor fits into your therapeutic paradigm for the individual patient.
Presenter
